A scientific publication in Cancers, a peer reviewed scientific journal, presents the capabilities of Acobiom’s GemciTest® to identify the pancreatic cancer patients who are most likely to benefit from gemcitabine-based treatment as the first approach.
In a recent study, ACOBIOM, in partnering with the Jerome Lejeune Institute, characterized molecular mechanisms that could help to better understand the decreased incidence of Breast Cancer in women with Down Syndrome (Trisomy 21).
AG2R LA MONDIALE supports the improvement of medical management of pancreatic cancer with GemciTest®
GemciTest®, an in-vitro diagnostic that predicts the patient’s response to one of the therapies used to treat pancreatic cancer, benefits now from CE marking, which means it complies with current European regulations in force. Acobiom develops innovative blood diagnostics in the field of precision medicine. These tests, based on liquid biopsies (blood), aim to give…
Read more
On next November 21, 2019, the World Pancreatic Cancer Day 2019 will be organized. Key information about pancreatic cancer Pancreatic cancer is one of the world’s deadliest cancers. This cancer develops when cells of the organs grow out of control, developing a tumor. The pancreas is a gland located deep in the abdomen, between the…
Read more
Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated with a clinical response to a specific therapy needs a tremendous combination of a scientific expertise, a biomolecular know-how, and a panel of bioinformatics and…
Read more
